(Reuters) - The U.S. Food and Drug Administration on Friday authorized booster doses of Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX)'s COVID-19 vaccine for all adults, a move aimed at addressing waning protection among fully vaccinated Americans in the face of Delta variant-driven breakthrough cases of the illness.
Earlier in the day, Moderna (NASDAQ:MRNA) said the FDA extended the emergency use authorization of a booster dose of its COVID-19 vaccine to all adults aged 18 and older.
A U.S. Centers for Disease Control and Prevention advisory panel is expected to meet later in the day to discuss whether to recommend the booster doses for the broader population.